Skip to main content
Jared Kelly

Jared Kelly

Nov 13, 2026

4:47
But does the offense change drastically, whether it's Hoover or Grant Wilson, or do they run schematically very similar no matter who's the signal caller?
4:56
Yeah, I think the system doesn't change holistically.
5:00
Even coming out of this bye week, Indiana probably did a bunch of self-scouting, as did USC.
5:05
And there's going to be some more wrinkles in there.
5:07
I would expect to see some more wrinkles, especially with Grant Wilson starting, because he is certainly more of a mobile quarterback than Josh Hoover.
5:13
We saw it against Minnesota in the second half.
5:15
Indiana was able to pull off a couple of read options that Grant Wilson kept and was able to do some things on the ground with.
7:18
How big of a loss is he? And what is your confidence level on his potential replacement?
25:16
But what do you think about the secondary holding back Ohio State's passing attack, and how, how will they contend with Jeremiah?
25:24
Yeah, I went into the off-season, you know, saying that D'Angelo Ponds, I thought, was the, the hardest player for Indiana to replace, even more so than Fernando, even more so than Aidan Fisher, uh, some of the other stars across that unit.
25:35
Just 'cause, uh, Indiana basically won him the games last year knowing that that third of the field, that half of the field that Ponds was on, um, if not locked up, at least you had, uh, some comfort level knowing that, that Ponds was not gonna allow, you know, too many explosive players over there.
25:48
Uh, to replace that is not easy.
25:50
Indiana brought in a Penn State transfer, AJ Harris, a former five-star, began his career at Georgia.
25:55
Thought that, that he w- that he would be kind of a plug-and-play answer there for Ponds.
25:59
Uh, he's been hurt since week one.

13 MINS LATER

38:59
Yeah.
22:16
Sure
22:16
... you have something that works in every time, then you got something bigger and very interesting.
22:22
But you take the tumor response data in a single arm, and you add that with the survival metrics that you mentioned, twenty-seven months overall survival, sixteen, uh, almost seventeen months of PFS, you combine those two together, that's what gives you a lot of confidence to say, "Well, we're having a lot of effect." You can cherry-pick survival in a single arm study, for example, because you can say, "Well, after they got ours, they got a bunch of other stuff that maybe worked better." You know? They were patients that were gonna live anyway.
22:52
You can always just kinda do that.
22:54
You can't fake tumor response and survival in the same study with the same fifteen, twenty patients, right? So that's, that's why we really felt confident in that data, and we had to do the full analysis.
23:06
'Cause frankly, the company had that study sitting, you know, on its shelf for four or five years and never did anything with it, and it, it was there for the taking.
23:15
You know, there was just, they were, the company was just focused on, you know, breast cancer and other, and, and running this goblet study that we've, you know, recently concluded.

12 MINS LATER

35:41
Sure
12:33
Yeah.
12:33
They're, they're basically playing with a fourth stringer in the national championship, and they, uh, you know, still managed to, to beat Miami in that game.
12:39
Um, and this year you could ar- uh, actually, I don't think you can argue.
12:43
I think it is pretty definitive, at least watching the spring, that this is a more talented, uh, uh, defensive line room when you consider who they bring back and what they brought in.
12:52
Uh, Mario Landino and, and Tyrik Tucker are your two in the middle at defensive tackle.
12:56
Tyrik Tucker was an All-American last year.
12:58
He's gonna be, uh, really the heartbeat of this defense.
16:11
Are you worried about the drop-off here?

We value your privacy

We use cookies to understand how you use our platform and to improve your experience. Click “Accept All” to consent, or “Decline non-essential” to opt out of non-essential cookies. Read our Privacy Policy.